LSD1 is a selective epigenetic target in SOX2-expressing cancer treatment, particularly in SOX2-rich carcinomas associated with small cell lung cancer (SCLC), ovarian cancer, and cervical cancer [55]. The gene discussed is SOX2; the disease is ovarian carcinoma.